Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC). This is an ASCO Meeting ...
NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.
Intravesical durvalumab appears promising for high-risk NMIBC after BCG failure or intolerance, according to preliminary study findings, and warrants further investigation. Intravesical durvalumab may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results